<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588247</url>
  </required_header>
  <id_info>
    <org_study_id>CENTER-study</org_study_id>
    <nct_id>NCT03588247</nct_id>
  </id_info>
  <brief_title>Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.</brief_title>
  <acronym>CENTER</acronym>
  <official_title>Cerebrovascular EveNts in Patients Undergoing TranscathetER Aortic Valve Implantation With Balloon-expandable Valves Versus Self-expandable Valves.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this collaborative analysis is to evaluate stroke rates and mortality in patients
      undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES
      valve. In the absence of large randomized controlled trials, we will conduct a large
      collaborative patient-pooled meta-analysis on 30-day stroke and mortality in patients
      undergoing primary transfemoral TAVI with either MCV or ES valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of this patient-pooled analyses is to compare stroke rates and mortality in
      patients undergoing TAVI with the self-expandable MCV prosthesis compared to the
      balloon-expandable ES valve. However, this collaboration may also be used to compare various
      outcomes.

      Studies were included if they complied with the following requirements: original prospective
      studies, including patients with aortic valve stenosis treated with transfemoral TAVI of
      native valves and reporting of 30 day stroke outcomes according to VARC criteria or other
      specified corresponding criteria . Moreover, to be included studies had to report both the
      use of self-expandable MCV prosthesis and the balloon-expandable ES valve in more than 50
      patients in each arm to ensure experience in use of the valves. Studies were excluded if they
      only addressed patients undergoing valve-in-valve and re-do procedures or bicuspid valves or
      included the same study population. Principal Investigators of these studies were approached
      for collaboration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death during the first month after TAVI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke during the first month after TAVI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Pacemaker during the first month after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major or life-threatening bleeding during the first month after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation</measure>
    <time_frame>30 days</time_frame>
    <description>New onset atrial fibrillation during the first month after TAVI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Myocardial infarction during the first month after TAVI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter aortic valve implantation</intervention_name>
    <description>Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergoing transfemoral transcatheter aortic valve procedures
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing transfemoral transcatheter aortic valve procedures

        Exclusion Criteria:

          -  valve-in-valve procedures, other acces routes than transfemoral
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jan Piek, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wieneke Vlastra, MD</last_name>
    <phone>+31205667883</phone>
    <email>w.vlastra@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronak Delewi, MD, PhD</last_name>
    <phone>+31205667883</phone>
    <email>r.delewi@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Piek, Prof.</last_name>
      <email>j.j.piek@amc.uva.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Jan Piek</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Collaborators are invited to participate in analyses</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

